The latest price target for AC Immune (NASDAQ: ACIU) was reported by HC Wainwright & Co. on August 7, 2023. The analyst firm set a price target for $16.00 expecting ACIU to rise to within 12 months (a possible 428.05% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for AC Immune (NASDAQ: ACIU) was provided by HC Wainwright & Co., and AC Immune reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AC Immune, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AC Immune was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.

While ratings are subjective and will change, the latest AC Immune (ACIU) rating was a reiterated with a price target of $0.00 to $16.00. The current price AC Immune (ACIU) is trading at is $3.03, which is within the analyst’s predicted range.

The latest price target for AC Immune (NASDAQ: ACIU) was reported by HC Wainwright & Co. on August 7, 2023. The analyst firm set a price target for $16.00 expecting ACIU to rise to within 12 months (a possible 428.05% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for AC Immune (NASDAQ: ACIU) was provided by HC Wainwright & Co., and AC Immune reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AC Immune, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AC Immune was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.

While ratings are subjective and will change, the latest AC Immune (ACIU) rating was a reiterated with a price target of $0.00 to $16.00. The current price AC Immune (ACIU) is trading at is $3.03, which is within the analyst’s predicted range.

The latest price target for AC Immune (NASDAQ: ACIU) was reported by HC Wainwright & Co. on August 7, 2023. The analyst firm set a price target for $16.00 expecting ACIU to rise to within 12 months (a possible 428.05% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for AC Immune (NASDAQ: ACIU) was provided by HC Wainwright & Co., and AC Immune reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AC Immune, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AC Immune was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.

While ratings are subjective and will change, the latest AC Immune (ACIU) rating was a reiterated with a price target of $0.00 to $16.00. The current price AC Immune (ACIU) is trading at is $3.03, which is within the analyst’s predicted range.

The latest price target for AC Immune (NASDAQ: ACIU) was reported by HC Wainwright & Co. on August 7, 2023. The analyst firm set a price target for $16.00 expecting ACIU to rise to within 12 months (a possible 428.05% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for AC Immune (NASDAQ: ACIU) was provided by HC Wainwright & Co., and AC Immune reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AC Immune, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AC Immune was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.

While ratings are subjective and will change, the latest AC Immune (ACIU) rating was a reiterated with a price target of $0.00 to $16.00. The current price AC Immune (ACIU) is trading at is $3.03, which is within the analyst’s predicted range.

The latest price target for AC Immune (NASDAQ: ACIU) was reported by HC Wainwright & Co. on August 7, 2023. The analyst firm set a price target for $16.00 expecting ACIU to rise to within 12 months (a possible 428.05% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for AC Immune (NASDAQ: ACIU) was provided by HC Wainwright & Co., and AC Immune reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AC Immune, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AC Immune was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.

While ratings are subjective and will change, the latest AC Immune (ACIU) rating was a reiterated with a price target of $0.00 to $16.00. The current price AC Immune (ACIU) is trading at is $3.03, which is within the analyst’s predicted range.

The latest price target for AC Immune (NASDAQ: ACIU) was reported by HC Wainwright & Co. on August 7, 2023. The analyst firm set a price target for $16.00 expecting ACIU to rise to within 12 months (a possible 428.05% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for AC Immune (NASDAQ: ACIU) was provided by HC Wainwright & Co., and AC Immune reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AC Immune, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AC Immune was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.

While ratings are subjective and will change, the latest AC Immune (ACIU) rating was a reiterated with a price target of $0.00 to $16.00. The current price AC Immune (ACIU) is trading at is $3.03, which is within the analyst’s predicted range.

The latest price target for AC Immune (NASDAQ: ACIU) was reported by HC Wainwright & Co. on August 7, 2023. The analyst firm set a price target for $16.00 expecting ACIU to rise to within 12 months (a possible 428.05% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for AC Immune (NASDAQ: ACIU) was provided by HC Wainwright & Co., and AC Immune reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AC Immune, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AC Immune was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.

While ratings are subjective and will change, the latest AC Immune (ACIU) rating was a reiterated with a price target of $0.00 to $16.00. The current price AC Immune (ACIU) is trading at is $3.03, which is within the analyst’s predicted range.

The latest price target for AC Immune (NASDAQ: ACIU) was reported by HC Wainwright & Co. on August 7, 2023. The analyst firm set a price target for $16.00 expecting ACIU to rise to within 12 months (a possible 428.05% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for AC Immune (NASDAQ: ACIU) was provided by HC Wainwright & Co., and AC Immune reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AC Immune, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AC Immune was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.

While ratings are subjective and will change, the latest AC Immune (ACIU) rating was a reiterated with a price target of $0.00 to $16.00. The current price AC Immune (ACIU) is trading at is $3.03, which is within the analyst’s predicted range.